PriceTargets.com logo

Bluejay Diagnostics - BJDX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.65 As of 12/3/2024 01:00 AM ET
▲ +0.12 (3.40%)

This chart shows the closing price for BJDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bluejay Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BJDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BJDX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Bluejay Diagnostics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.65.

This chart shows the closing price for BJDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Bluejay Diagnostics. This rating has held steady since July 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/3/2023Dawson JamesDowngradeBuy ➝ Neutral
1/12/2022Dawson JamesInitiated CoverageBuy$80,000.00
(Data available from 12/4/2019 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Bluejay Diagnostics logo
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Read More

Today's Range

Now: $3.65
Low: $3.42
High: $3.92

50 Day Range

MA: $4.96
Low: $3.24
High: $7.25

52 Week Range

Now: $3.65
Low: $3.03
High: $1,564.00

Volume

81,478 shs

Average Volume

961,881 shs

Market Capitalization

$1.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Bluejay Diagnostics?

The following Wall Street sell-side analysts have issued stock ratings on Bluejay Diagnostics in the last twelve months:
View the latest analyst ratings for BJDX.

What is the current price target for Bluejay Diagnostics?

0 Wall Street analysts have set twelve-month price targets for Bluejay Diagnostics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Bluejay Diagnostics in the next year.
View the latest price targets for BJDX.

What is the current consensus analyst rating for Bluejay Diagnostics?

Bluejay Diagnostics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BJDX.

What other companies compete with Bluejay Diagnostics?

Other companies that are similar to Bluejay Diagnostics include Plus Therapeutics, Intelligent Bio Solutions, Tenon Medical, Carmell and Biotricity. Learn More about companies similar to Bluejay Diagnostics.

How do I contact Bluejay Diagnostics' investor relations team?

The company's listed phone number is 844-327-7078 and its investor relations email address is [email protected]. The official website for Bluejay Diagnostics is www.bluejaydx.com. Learn More about contacing Bluejay Diagnostics investor relations.